KWKevin P. Walsh

Kevin P. Walsh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kevin P. Walsh has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Early clinical experience with a modified amplatzer ductal occluder for transcatheter arterial duct occlusion in infants and small children

    by Damien Kenny, Gareth J. Morgan, James R. Bentham, Neil Wilson, Robin Martin, Andrew Tometzki, Paul Oslizlok, Kevin P. Walsh

    Objectives To describe early clinical experience with the amplatzer ductal occluder II additional sizes (ADO II AS) for percutaneous arterial duct occlusion in infants and small children. Methods Pre-, intra- and postprocedural data analysis of all patients undergoing arterial duct occlusion with the ADO II AS from three tertiary referral centers. Results 17 patients (10 female) with a median age of 6 months (range 1.0–48.1 months) and a median weight of 5.7 kg (range 1.7–17.4 kg) underwent attempted transcatheter ductal closure with the ADO II AS. Retrograde arterial approach was used in eight patients with transvenous femoral approach used in nine. The mean minimal ductal diameter was 2.2 ± 0.7 mm with mean ductal length of 6.8 ± 1.7 mm. Device sizes used were 5/6 (n = 5), 3/4 (n = 4), 4/4 (n = 3), 4/6 (n = 3), and 5/4 (n = 2) with four French delivery sheaths used in all cases. The median fluoroscopy time was 5.7 ± 1.8 min. Two patients underwent delivery under exclusive echocardiography guidance. Complete ductal occlusion was achieved by the end of the procedure in 13 patients. Device embolization to the left pulmonary artery occurred in one patient with successful surgical removal and ligation of the arterial duct. Three patients required device resizing following deployment of the initial device. Complete ductal occlusion without aortic arch or left pulmonary artery stenosis has been identified in all 16 remaining patients on transthoracic echocardiographic follow-up at median of 4.2 months. Conclusions The new amplatzer ductal occluder II AS achieves excellent ductal closure rates through low profile delivery systems in small infants and children with variable ductal anatomy.


  • Transcatheter tricuspid valve replacement With the Edwards SAPIEN valve

    by Damien Kenny, Ziyad M. Hijazi, Kevin P. Walsh

    We describe a case of percutaneous tricuspid valve implantation in a 20-year-old man with previous tricuspid valve replacement in the setting of pulmonary atresia with intact ventricular septum. He developed symptomatic endocarditis-induced tricuspid regurgitation of the tricuspid bioprosthesis. Tricuspid valvar competence was restored with implantation of a 26-mm Edwards SAPIEN valve.


  • Transhepatic Approach for Extracardiac Inferior Cavopulmonary Connection Stent Fenestration

    by Damien Kenny, Colin McMahon, Kevin P. Walsh

    We report on a 3-year-old male who underwent transcatheter stent fenestration of the inferior portion of an extracardiac total cavopulmonary connection in the setting of hypoplastic left heart syndrome. Transhepatic approach, following an unsuccessful attempt from the femoral vein facilitated delivery of a diabolo-shaped stent.


  • Transcatheter occlusion of a classical BT shunt with the Amplatzer Duct Occluder II

    by Damien Kenny, Kevin P. Walsh

    We report on a 57‐year‐old woman who underwent transcatheter occlusion of a residual classical Blalock‐Taussig shunt with the Amplatzer® Duct Occluder II (ADO II) 35 years following definitive surgical correction for tetralogy of Fallot.


  • Noncatheter‐Based Delivery of a Single‐Chamber Lumenless Pacing Lead in Small Children

    by Damien Kenny, Kevin P. Walsh

    Objectives: The model 3830 lead (SelectSecure™ Medtronic, Minneapolis, MN, USA) is a bipolar, fixed‐screw, 4.1‐F pacing lead designed for site‐selective pacing. Implantation is usually performed using an 8‐F deflectable catheter system. This catheter is not ideal for smaller children because of both the sheath size and the relatively large deflected curves. We describe a simpler noncatheter‐based delivery system in seven children. Methods: A 4.1‐F SelectSecure lead was introduced via a 5‐F SafeSheath (Thomas Medical, Malvern, PA, USA) placed in the left subclavian vein. The SelectSecure lead was passed into the inferior vena cava (IVC) and a loop created, which was then withdrawn into the right atrium. Once in position, the lead was screwed into the myocardium, the SafeSheath was peeled off, and the lead connected to the generator. Results: From March 2005 until September 2006, five right atrial leads and two right ventricular leads were implanted in seven patients (six female) with a median weight of 15 kg (8.1–19.4). All leads were successfully placed with excellent pacing thresholds. The median screening time was 7.1 minutes (4.8–11.4) with a median radiation dose of 83 cGy cm2. There were no procedural complications and no lead displacements seen on a median follow‐up of 10 months. Conclusions: Delivery of the 4.1‐F SelectSecure pacing lead to the right heart is possible using a noncatheter‐based delivery system. This is effective and safe and does not require the use of a larger delivery system. This allows these thin isodiametric pacing leads to be used advantageously in small children.


  • Percutaneous closure of postoperative ventricular septal defects with the amplatzer device

    by Mark A. Walsh, David M. Coleman, Paul Oslizlok, Kevin P. Walsh

    The objective of this study was to look at the procedure, the results, and the follow-up of patients who underwent percutaneous closure of a residual ventricular septal defect (VSD) following a surgical closure using the Amplatzer VSD device. Four patients had an original diagnosis of tetralogy of Fallot, two patients had a patch leak following a surgical repair of a VSD, and three patients had a VSD not repaired at the time of surgery. All patients fulfilled the currently accepted surgical criterion for reoperation (Qp/Qs > 1.5). The mean Qp/Qs was 1.8 ± 0.3 (1.5–2.3). Four patients underwent VSD closure using an Amplatzer perimembranous VSD device and in five patients an Amplatzer muscular VSD device was implanted. We performed percutaneous closure in nine patients. The size of the residual shunt ranged from 6 to 14 mm and the size of device used ranged from 8 to 16 mm. The arteriovenous loop needed to be recreated in two patients because of failure to advance the delivery sheath. There was complete closure of the defect in six cases, and a small residual shunt remained in three cases. Percutaneous closure of postoperative VSDs appears to be an effective way to resolve a hemodynamically significant residual shunt. There were no difficulties encountered with implantation of the devices. These promising short-term results need reinforcement with additional long-term data.


  • Open Access

    Atrioventricular block after transcatheter closure of perimembranous ventricular septal defects

    by M A Walsh, J Bialkowski, M Szkutnik, M Pawelec-Wojtalik, W Bobkowski, K P Walsh

    Objective: To look at the presentation, treatment and outcome of patients who developed atrioventricular block after transcatheter closure of a perimembranous ventricular septal defect (PMVSD) with the Amplatzer PMVSD device. Setting: Three tertiary referral centres for paediatric cardiology in two countries. Results: All three patients presented within 10 days of the procedure. All three patients were treated with intravenous steroids. A permanent pacemaker was inserted in all patients but no pacemaker required activation after two months. Conclusion: Complete atrioventricular block occurring in the weeks after device occlusion of a PMVSD appears to resolve quickly. Continued involvement in multicentre device databases is required to monitor safety.


  • The Amplatzer septal occluder

    by Kevin P. Walsh, Ismail M. Maadi

    The Amplatzer Septal Occluder is made from a Nitinol wire mesh shaped into 2 disks with a connecting waist, which serves to center the device in the defect while occluding it. The Amplatzer device is also available in a configuration with no central waist for use in patients with patent oval foramen, or multiperforated aneurysm of the interatrial septum. For the purposes of this review, we analysed our experience using the Amplatzer device in 150 patients with interatrial communications. Of these, 104 had a defect within the oval fossa, 33 a patent oval foramen, and 13 had undergone fenestration of a Fontan procedure. Of those with defects within the oval fossa, a device was implanted in 100 patients, and 2 of these patients subsequently required surgical intervention, 1 because of migration and the other because of malformation of the device. Of the remaining 98 patients, complete occlusion has been achieved in 90% at 1 year. Any residual leaks are either trivial or small. In those with a patent oval foramen, the septal occluder was used to close 20, whilst the device designed specifically for this purpose was used in 13. On follow-up contrast echocardiography, only 2 patients have a small residual right-to-left shunt. Complete occlusion was achieved for all the Fontan fenestrations, although 1 patient later underwent surgery for baffle dehiscence. Other significant complications occurred in 2 patients who developed deep vein thrombosis, and 3 patients who suffered transient supraventicular arrhythmias. Although the Amplatzer device has been in clinical use for only 3 years, its unique design, and ease of use, has resulted in its widespread adoption by many entres. The results to date are very encouraging, but it must be remembered that there is, as yet, no long-term followup data available for this life-long implant.